source
- Celcuity's gedatolisib trial cuts death risk but misses investor expectationsCelcuity reported data from its Phase 3 VIKTORIA-1 trial evaluating gedatolisib in HR‑positive, HER2‑negative breast cancer with PIK3CA mutations. The trial enrolled 350 patients who had progresse…
- Eli Lilly gives 340B hospitals a week to share data or lose drug discountsEli Lilly has told hospitals and medical groups that participate in the 340B drug discount program that they must submit claims data for all Lilly medications by the coming Monday, or they will be…